Jo Vandesompele,
Professor,
Ghent University and CSO, Biogazelle
Jo Vandesompele is full professor in Functional Cancer Genomics and Applied Bioinformatics at Ghent University, Belgium. He obtained a Master of Science in Bioscience Engineering (1997) and a PhD in Medical Genetics (2002). He is author of more than 200 scientific articles in international journals, including some pioneering publications in the domain of RNA quantification. His H-index is 72, with over 40 000 citations (Web of Science, February 2018).
The main themes of his research are the study of non-coding RNAs in cancer and the development of nucleic acid quantification methods. His lab uses a combination of high-throughput (functional) genomics technologies and bio-informatics tools to answer the various research questions in the field of cancer.
Currently, the lab is doing active research in the field of liquid biopsy enabled precision oncology space, in which the preanalytical steps of sample collection, processing and storage are scrutinized and novel methods are developed for mRNA expression profiling enabling somatic variant analysis.
Jo is also co-founder and CSO of Biogazelle, is a Ghent University spin-off company (2007), and co-founder of pxlence (UGent spin-off 2015).
Exploiting RNA In Liquid Biopsies For Precision Medicine Purposes
Wednesday, 30 October 2019 at 17:15
Add to Calendar ▼2019-10-30 17:15:002019-10-30 18:15:00Europe/LondonExploiting RNA In Liquid Biopsies For Precision Medicine PurposesCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
In contrast to general belief, a substantial part of the human transcriptome is abundantly present in the blood and other biofluids as extracellular messenger RNA, long non-coding RNAs and various small RNAs, ready to exploited. I will discuss various workflows for RNA sequencing of biofluid derived RNA, including probe-based target capture and unbiased total RNA library prep as sensitive RNA sequencing workflow to study thousands of mRNA and lncRNA genes in cell-free RNA from patients’ plasma and other biofluids. Apart from RNA abundance profiling, this type of data can also be used to detect structural RNA variants, such as somatic mutations, fusion genes and RNA editing events, all known to play an important role in disease, including cancer. The resulting RNA profiles can be deconvoluted to enumerate the cells, tissues and organs that contribute to the extracellular RNA. Human biofluid RNA sequencing enables liquid biopsy guided precision oncology, such as therapy stratification, treatment response monitoring and early detection of relapse. I will also discuss the pre-analytical jungle of RNA targeted liquid biopsies and need for standardization, as part of the ongoing extracellular RNA quality control study. I will end with the first insights of the Human Biofluid RNA Atlas, in which we have deeply probed into the extracellular transcriptome of 22 human biofluids, providing a solid foundation for exploiting biofluids for diagnostic purposes.
Add to Calendar ▼2019-10-30 00:00:002019-11-01 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-10-30 17:15:002019-10-30 18:15:00Europe/LondonExploiting RNA In Liquid Biopsies For Precision Medicine PurposesCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
